Continental Advisors LLC Trims Holdings in AstraZeneca plc (AZN)
Continental Advisors LLC cut its holdings in shares of AstraZeneca plc (NYSE:AZN) by 4.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 98,300 shares of the company’s stock after selling 5,000 shares during the period. Continental Advisors LLC’s holdings in AstraZeneca were worth $3,411,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in AZN. Pinnacle Wealth Planning Services Inc. acquired a new stake in AstraZeneca during the 4th quarter worth approximately $101,000. Valeo Financial Advisors LLC acquired a new stake in AstraZeneca during the 3rd quarter worth approximately $133,000. Delpha Capital Management LLC acquired a new stake in AstraZeneca during the 4th quarter worth approximately $152,000. Calton & Associates Inc. acquired a new stake in AstraZeneca during the 4th quarter worth approximately $181,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in AstraZeneca during the 3rd quarter worth approximately $184,000. Institutional investors own 14.91% of the company’s stock.
Shares of AstraZeneca plc (NYSE AZN) opened at $33.16 on Friday. AstraZeneca plc has a one year low of $28.43 and a one year high of $36.70. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80. The company has a market cap of $83,987.32, a price-to-earnings ratio of 7.75, a P/E/G ratio of 1.98 and a beta of 0.71.
The business also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Thursday, February 15th. This represents a yield of 5.62%. AstraZeneca’s dividend payout ratio is currently 57.81%.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 3rd. Leerink Swann raised their price objective on shares of AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a report on Tuesday, February 6th. BMO Capital Markets set a $40.00 price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. upgraded shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $36.26.
COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/continental-advisors-llc-trims-holdings-in-astrazeneca-plc-azn/1906442.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.